MARKET

MNTA

MNTA

Momenta Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.91
-0.64
-2.22%
After Hours: 27.77 -0.14 -0.49% 16:11 08/11 EDT
OPEN
28.59
PREV CLOSE
28.55
HIGH
28.59
LOW
26.86
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
39.88
52 WEEK LOW
11.29
MARKET CAP
3.29B
P/E (TTM)
-9.9818
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNTA stock price target is 45.25 with a high estimate of 53.00 and a low estimate of 36.00.

EPS

MNTA News

More
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 1d ago
OMER, TRVN, KODK and NAVB among midday movers
Seeking Alpha - Article · 1d ago
Momenta Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Benzinga · 1d ago
Momenta Pharmaceuticals Q2 EPS $(0.48) Misses $(0.39) Estimate, Sales $6.61M Beat $5.56M Estimate
Momenta Pharmaceuticals (NASDAQ:MNTA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 58.62 percent increase over losses of $(1.16) per
Benzinga · 1d ago
Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will rel
GlobeNewswire · 08/03 11:30
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/31 16:30
Momenta's nipocalimab nabs Rare Pediatric Disease tag for anemia in newborns
The FDA has signed off on Rare Pediatric Disease designation for Momenta Pharmaceuticals' (NASDAQ:MNTA) nipocalimab for the prevention of hemolytic disease
seekingalpha · 07/28 17:31
Momenta Pharmaceuticals shares are trading higher after the company announced it has received FDA rare pediatric disease designation for Nipocalimab in HDFN.
Benzinga · 07/28 14:02

Industry

Biotechnology & Medical Research
-2.36%
Pharmaceuticals & Medical Research
-0.93%

Hot Stocks

Symbol
Price
%Change

About MNTA

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.
More

Webull offers kinds of Momenta Pharmaceuticals, Inc. stock information, including NASDAQ:MNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNTA stock methods without spending real money on the virtual paper trading platform.